Trial record 1 of 1 for:    WVU 11310
Previous Study | Return to List | Next Study

Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2014 by West Virginia University
Information provided by (Responsible Party):
Dr. Abraham Kanate, West Virginia University Identifier:
First received: September 13, 2010
Last updated: December 8, 2014
Last verified: December 2014
No Study Results Posted on for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2016
  Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)